Delivery Order SPE2DB20D2104-SPE2DB22FR65M
- Not listed
- This federal contract award, valued at $1,212.73, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor, Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of 4,563,557,309 units of Lisinopril 40 mg tablets. It is a firm-fixed-price delivery order contract with a completion date of February 6, 2024. There is no set-aside designation for this award. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery...
- This federal contract award is for the delivery of Lisinopril 40 mg tablets in quantities of 1,000 to the U.S. government. The contract, valued at $3,503.44, was awarded by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has a completion date of December 8, 2023 and is a Firm Fixed Price Delivery Order. The contract was not set aside for any specific business type....
- This federal contract award is for the delivery of Lisinopril 40 mg tablets to the Defense Logistics Agency (DLA) Troop Support Medical. The contract was awarded to AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., for a firm fixed price of $2,423.08. The contract does not have a set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 1,000 units of the medication Lisinopril 40 mg tablets. The contract has a firm fixed price of $1,053.60 and a completion date of May 6, 2025. This award is not associated with a set-aside program and is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999.00,...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the procurement of 1,000 tablets of the generic drug Lisinopril 40 mg, which is used to treat high blood pressure and other cardiovascular conditions. The firm-fixed-price contract has a ceiling value of $1,591.22 and an ultimate completion date of January 30, 2025. This award is not associated...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,148.59 firm fixed-price delivery order is for lisinopril 40 mg tablets, a medication used to treat high blood pressure and heart failure. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which serves as a primary vehicle...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,556,110,689 lisinopril 20 mg tablets in lots of 1,000. This $1,056.28 award is not associated with any set-aside designation. Amerisourcebergen Drug Corp is the prime contractor on a larger $999,999,999.00 indefinite delivery contract with DLA to deliver pharmaceutical products and medical...
- This federal contract award is for the delivery of Lisinopril 40 mg tablets, with a ceiling value of $4,562.92, awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is a Delivery Order awarded by the Defense Logistics Agency (DLA) Troop Support Medical, a defense agency, and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award, with ID SPE2DB24D1205|SPE2DB25FCUFU, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which is a Delivery Order valued at $3,954.02, is for the delivery of 4,567,342,826 units of Lisinopril 40 mg tablets. The contract has a final completion date of February 24, 2025 and was awarded on February 21, 2025. Amerisourcebergen Drug Corp is the prime...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,178.24, is for the delivery of 4,556,005 units of the drug Lisinopril 20 mg tablets. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., which is valued at up to $999,999,999.00 and runs through...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB22FR65MDelivery Order
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, provides Lisinopril 40 mg tablets to the Defense Logistics Agency (DLA) for $3,076.92. The award is a delivery order under an Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 that Amerisourcebergen's parent company, Cencora, Inc., holds with the DLA Troop Support Medical. This IDC serves as the primary vehicle for Cencora to deliver a wide range of pharmaceutical products and medical supplies to support military and veteran healthcare programs globally. The contract does not have a set-aside designation, indicating open competition. As a key vendor for federal healthcare programs, Amerisourcebergen supplies essential medications, vaccines, devices, and other medical commodities across multiple therapeutic areas to the Department of Defense and other government agencies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.1k | 1/27/22 |